Opna Bio discovers and develops novel oncology therapeutics by targeting key regulators of cancer pathways. The company is advancing epigenetic inhibitors, including the BET inhibitor zavabresib for myelofibrosis and the EP300 inhibitor OPN-6602 for multiple myeloma. These clinical-stage programs aim to provide differentiated safety and efficacy profiles for hematologic malignancies.
Funding
$38M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Many cancers evade detection and destruction by the immune system through mechanisms like immune suppression and epigenetic reprogramming. Current cancer treatments often fail to address these resistance mechanisms, leading to suboptimal efficacy and disease progression.
Solution
Opna Bio develops targeted therapeutics designed to inhibit key regulators of immune suppression and epigenetic reprogramming in cancer cells. Their pipeline includes compounds like OPN-2853, a BET inhibitor, and OPN-6602, a dual inhibitor of EP300 and CBP, both of which are currently in clinical development. By targeting these master regulators, Opna Bio aims to enhance the efficacy of cancer treatments by preventing tumor cells from evading immune detection and promoting uncontrolled growth. Their approach focuses on nonmutational epigenetic reprogramming and avoiding immune destruction, addressing key hallmarks of cancer.
Target Audience
Opna Bio's primary target audience includes patients with hematologic malignancies such as multiple myeloma and myelofibrosis, as well as those with solid tumors.
Features
- OPN-2853: A BET inhibitor in Phase 1 clinical trials for advanced myelofibrosis, often used in combination with Ruxolitinib.
- OPN-6602: A best-in-class EP300/CBP inhibitor in Phase 1 clinical trials for relapsed/refractory multiple myeloma.
- OPN-FMRP: An FMRP inhibitor targeting solid tumors by addressing immune evasion.
- OPN-7486: A compound in preclinical development.
- OPN-9840: A compound in preclinical development.
- OPN-9627: A compound in preclinical development.
- Focus on epigenetic inhibitors with differentiated pharmacokinetics (PK) for improved safety and efficacy.